Hepatitis B market to be contested by 3 pharmaceutical firms

Published: 2006-08-02 06:59:00

Updated: 2006-08-02 06:59:00

Pharmaceutical business sources that domestic hepatitis B market will emerge as an arena of tripartite competition GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefovir), Bukwang Pharm's Levovir (clevudine) and BMS Korea's BARACLUDE (entecavir).

Levovir, the first-domestically-made medication for hepatitis B, will challenge Zeffix and Hepsera.

It received approval from the nation's...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.